CytoSorbents Corporation (HQE1)
XSTU
Real-time Data
06:00 AM
Day's Range
5.9252 wk Range
0.2980Overview - HQE1 - CytoSorbents Corporation
Key Statistics
Valuation
Enterprise Value
22.86M
P/E (Trailing)
‪-2.27‬
PEG Ratio
‪0.00047‬
Price / Book
‪-24.75‬
EV / EBITDA
‪-1.73‬
Profitability
Gross Margin
‪73.17%‬
Profit Margin
‪71.47%‬
Operating Margin
‪-16.15%‬
Return on Assets
‪-18.55%‬
Return on Equity
‪-138.87%‬
Ownership
Shares Outstanding
3.14M
Price stats
50-Day Avg
‪0.5774‬
200-Day Avg
‪0.7315‬
Peers - HQE1 - CytoSorbents Corporation
Peer Comparison
Compared with companies in Medical Devices listed on XSTU.
- HQE1XSTUCytoSorbents Corporation+94.73%52-week change-2.28P/E (Trailing)‪71.47%‬Profit Margin
- PENXSTUPBF Energy Inc.+68.22%52-week change7.71P/E (Trailing)‪3.93%‬Profit Margin
- LT3XSTUAxogen, Inc.+61.76%52-week change-111.53P/E (Trailing)‪74.31%‬Profit Margin
- NG2XSTUNeogen Corp.+60.50%52-week change-300.00P/E (Trailing)‪46.93%‬Profit Margin
- 51KBXSTUAVITA Medical, Inc.+55.59%52-week change-6.12P/E (Trailing)‪82.13%‬Profit Margin
- HAZXSTUHaemonetics Corporation+53.04%52-week change44.61P/E (Trailing)‪59.03%‬Profit Margin
- 6GJXSTUGlaukos Corp.+49.26%52-week change-41.16P/E (Trailing)‪55.72%‬Profit Margin
Profile Summary - HQE1 - CytoSorbents Corporation
About
CytoSorbents Corporation is a medical device company focused on blood purification technologies for critical care and cardiac surgery. CytoSorbents Corporation develops and commercializes products that use hemoadsorption to remove harmful substances from blood, including inflammatory mediators, bilirubin, myoglobin,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
